Clinical trial · Interventional
Oral Supplementation of Glutamine on Gastric Cancer Patients After Gastrectomy
NCT06027242CI-TRIAL-00099570recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Glutamine has the potentials of immunomodulation and adjustment of protein metabolism. The primary objective of this study is to evaluate the efficacy of glutamine on sarcopenia in gastric adenocarcinoma patients undergoing gastrectomy. The secondary endpoints, including the physical activity, weight loss, and nutritional profiles, will be evaluated among these patients.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
| Gastrostomy | — | UNRESOLVED | — |
| Immunonutrition | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Maltodextrin | Dietary Supplement | — | UNRESOLVED |
| oral glutamine | Dietary Supplement | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- PLACEBO_COMPARATOR
- label
- Without oral glutamine supplementation
- description
- 15 g Maltodextrin for 28 days after surgery with tolerable oral intake or enteral feeding
- interventionNames
- Dietary Supplement: Maltodextrin
- type
- ACTIVE_COMPARATOR
- label
- With oral glutamine supplementation
- description
- 10 g glutamine +5 g Maltodextrin for 28 days after surgery with tolerable oral intake or enteral feeding
- interventionNames
- Dietary Supplement: oral glutamine
- Dietary Supplement: Maltodextrin
Primary outcomes (1)
- measure
- Change of area of psoas muscle
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
Show eligibility criteria text
Inclusion Criteria: * adult gastric cancer receiving gastrectomy Exclusion Criteria: * Hepatic insufficiency * Renal insufficiency * can not tolerate oral or enteral feeding 7 days after gastrectomy * can not receive computed tomograph * can not waer the wearable devices
References
Publications (0)
Data not yet available
No reference posted for this study.